We experience the burden of cancer here in Georgia and throughout the U.S., but cancer is not just an American problem. It is the leading cause of death worldwide. According to the World Health Organization, cancer accounted for 7.6 million deaths (about 13% of all deaths) in 2008 and that number is projected to rise to 13.1 million deaths in 2030.
Every day, my Winship colleagues and I seek to identify better ways to prevent, treat, and ultimately cure cancer. Fortunately, we do not work in isolation. Our efforts are part of a global collaborative of cancer researchers and doctors, and one of the most rewarding aspects of this work is joining forces with scientists from all over the world who are committed to a shared goal of ending cancer.
Imagine a global community of scientists in continual conversation about the most up-to-date mindset for treating cancer. We are a vital part of that conversation.
I made two international trips late last year which captured the spirit of collaboration in cancer research. One trip was to Australia, stopping first at the World Conference on Lung Cancer in Sydney, and then on to Brisbane, where a unique partnership called the Queensland Emory Development Alliance (QED) is bringing together outstanding researchers from Emory, The University of Queensland (UQ) and the Queensland Institute of Medical Research (QIMR), to collaborate on new research projects primarily in the realm of cancer and infectious disease.
Several Winship faculty including William Dynan and Dennis Liotta are currently collaborating on cancer research projects with new colleagues at UQ and QIMR. My visit to Brisbane has resulted in early work towards furthering these and other collaborations. The World Conference on Lung Cancer in Sydney highlighted a number of important findings in our struggle against the leading cancer killer resulting from work conducted among my colleagues in Asia, Europe, and the United States.
In December, I flew to Chengdu, China, as a guest of the Chinese Society of Radiation Oncology (CSTRO) to deliver the keynote address at the annual CSTRO Symposium. As evidenced in this conference and in my subsequent visits to large cancer centers in Bejing and Jinan, there have been remarkable advances in cancer research and cancer care in China. There is also a tremendous level of collaboration between investigators at major Chinese universities and faculty at Winship and other major American cancer centers. Currently my colleagues and I are working each week on a clinical trial underway at eight Chinese cancer centers, comparing stereotactic radiation to surgery for patients with early stage lung cancer. I had a chance to meet with all of my colleagues conducting this research in China during my visit there and to celebrate this progress!
I’m extremely proud of the work performed here at Winship that contributes to advancing cancer research throughout the world. International conferences, as well as the many times we host scientists from other countries here on the Emory campus, enable us to share information and resources and benchmark our own contributions. But it’s when I return to Winship and see patients who are benefiting from discoveries made by my colleagues here and elsewhere, the value of collaboration truly hits home.
Seeing even one patient improve from the advances we make in cancer research and treatment is a reward worth sharing with the world.
*February 4th is World Cancer Day, when international health organizations support the Union for International Cancer Control (UICC) in promoting ways to ease the global burden of cancer. This year’s theme, “Debunk the myths,” focuses on improving general knowledge about cancer in order to reduce stigma and dispel misconceptions about the disease. More information: http://www.worldcancerday.org
Author: Walter J. Curran, Jr., MD, executive director, Winship Cancer Institute
About Dr. Walter Curran
Walter J. Curran, M.D. was appointed Executive Director of Winship Cancer Institute of Emory University in 2009. He joined Emory in January 2008, as the Lawrence W. Davis Professor and Chairman of Emory’s Department of Radiation Oncology. He also serves as Group Chairman and Principal Investigator of the Radiation Therapy Oncology Group (RTOG), a National Cancer Institute-funded cooperative group, a position he has held since 1997. Curran has been named a Georgia Research Alliance Eminent Scholar and Chair in Cancer Research as well as a Georgia Cancer Coalition Distinguished Cancer Scholar.
Dr. Curran has been a principal investigator on over thirty National Cancer Institute-supported grants and is considered an international expert in the management of patients with locally advanced lung cancer and malignant brain tumors. He has led several landmark clinical and translational trials in both areas and is responsible for defining a universally adopted staging system for patients with malignant glioma and for leading the randomized trial which defined the best therapeutic approach to patients with locally advanced lung cancer. He serves as the Founding Secretary/Treasurer of the Coalition of Cancer Cooperative Groups and is a Board Member of the Georgia Center for Oncology Research and Education (Georgia CORE). Dr. Curran is the only radiation oncologist to have ever served as Director of a National Cancer Institute-Designated Cancer Center.
Dr. Curran is a Fellow in the American College of Radiology and has been awarded honorary memberships in the European Society of Therapeutic Radiology and Oncology and the Canadian Association of Radiation Oncology. According to the Blue Ridge Institute for Medical Research, Dr. Curran ranked among the top ten principal investigators in terms of National Cancer Institute grant awards in 2013, and was first among investigators in Georgia, and first among cancer center directors.